The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

Setareh Moghadasi, Huong D. Meeks, Pg Maaike Vreeswijk, Linda A.M. Janssen, Åke Borg, Hans Ehrencrona, Ylva Paulsson-Karlsson, Barbara Wappenschmidt, Christoph Engel, Andrea Gehrig, Norbert Arnold, Thomas Van Overeem Hansen, Mads Thomassen, Uffe Birk Jensen, Torben A. Kruse, Bent Ejlertsen, Anne Marie Gerdes, Inge Søkilde Pedersen, Sandrine M. Caputo, Fergus CouchEmily J. Hallberg, Ans M.W. Van Den Ouweland, Margriet J. Collée, Erik Teugels, Muriel A. Adank, Rob B. Van Der Luijt, R. Arjen Mensenkamp, Jan C. Oosterwijk, Marinus J. Blok, Nicolas Janin, Kathleen B.M. Claes, Kathy Tucker, Valeria Viassolo, Amanda Ewart Toland, Diana E. Eccles, Peter Devilee, Christie J. Van Asperen, Amanda B. Spurdle, David E. Goldgar, Encarna Gómez García

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium'. Together they form a unique fingerprint.

Medicine & Life Sciences